Adaptimmune-Genentech allogeneic T-cell collaboration terminated; focus on afami-cel PDUFA Aug 4

Adaptimmune Therapeutics PLC

Genentech terminates 2021 collaboration on allogeneic T-cell therapies; termination effective ~Oct 7, 2024.
Adaptimmune received $150M upfront and $35M milestones; no further milestones or payments due.
Company reaffirms focus on afami-cel launch; PDUFA target date August 4, 2024; Investor Day April 18.
Adaptimmune retains all rights to its iPSC-based allogeneic platform and autologous pipeline.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Adaptimmune Therapeutics PLC terminated Strategic Collaboration and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (effective 2024-04-10).

Action: termination
Agreement: collaboration
Counterparty: Genentech, Inc. and F. Hoffman-La Roche Ltd.
Effective: 2024-04-10

Exact text from the filing

On April 10, 2024, Adaptimmune Limited, a wholly-owned subsidiary of Adaptimmune Therapeutics plc (“Adaptimmune”) received notice of termination of the Strategic Collaboration and License Agreement with Genentech, Inc. (“Genentech”) and F. Hoffman-La Roche Ltd. (the “Agreement”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001558370-24-004997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.